Circadian gene variants in cancer

Annals of Medicine

Volumn 46, Issue 4, 2014, Pages 208-220

  Kettner, Nicole M ^a,b   Katchy, Chinenye A ^b   Fu, Loning ^a,b  

^a CHILDREN S NUTRITION RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Cancer risk factors; Cell cycle; Cellular senescence; Circadian rhythm; DNA damage response; Metabolism; Molecular clock; Social jet lag; Tumor suppression

Indexed keywords

APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CELL METABOLISM; CELL PROLIFERATION; CIRCADIAN RHYTHM; DNA DAMAGE; DNA REPAIR; EPIGENETICS; FEEDBACK SYSTEM; GENE MUTATION; GENE TARGETING; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; MOLECULAR CLOCK; NEOPLASM; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETICS; MUTATION; PATHOLOGY; PHYSIOLOGY; RISK FACTOR;

ANIMALS; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; GENETIC VARIATION; HOMEOSTASIS; HUMANS; MUTATION; NEOPLASMS; RISK FACTORS;

EID: 84902207766     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.914808     Document Type: Article

References (303)

1. Evans JA, Davidson AJ. Health consequences of circadian disruption in humans and animal models. Prog Mol Biol Transl Sci. 2013; 119: 283-323.
2. Foster RG, Peirson SN, Wulff K, Winnebeck E, Vetter C, Roenneberg T. Sleep and circadian rhythm disruption in social jetlag and mental illness. Prog Mol Biol Transl Sci. 2013; 119: 325-46.
3. Zhang L, Ptacek LJ, Fu YH. Diversity of human clock genotypes and consequences. Prog Mol Biol Transl Sci. 2013; 119: 51-81.
4. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013; 119: 221-82.
5. Moore RY. The suprachiasmatic nucleus and the circadian timing system. Prog Mol Biol Transl Sci. 2013; 119: 1-28.
6. Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci. 2001; 2: 521-6.
7. Buijs R, Salgado R, Sabath E, Escobar C. Peripheral circadian oscillators: time and food. Prog Mol Biol Transl Sci. 2013; 119: 83-103.
8. Buhr ED, Takahashi JS. Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. 2013(217): 3-27.
9. Padmanabhan K, Robles MS, Westerling T, Weitz CJ. Feedback regulation of transcriptional termination by the mammalian circadian clock PERIOD complex. Science. 2012; 337: 599-602.
10. Gallego M, Virshup DM. Post-translational modifications regulate the ticking of the circadian clock. Nat Rev Mol Cell Biol. 2007; 8: 2139-48.
11. Kojima S, Shingle DL, Green CB. Post-transcriptional control of circadian rhythms. J Cell Sci. 2011; 124(Pt 3): 311-20.
12. Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, et al. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science. 2012; 338: 349-54.
13. Ueda HR. Systems biology of mammalian circadian clocks. Cold Spring Harb Symp Quant Biol. 2007; 72: 365-80.
14. Eckel-Mahan K, Sassone-Corsi P. Epigenetic regulation of the molecular clockwork. Prog Mol Biol Transl Sci. 2013; 119: 29-50.
15. Hirota T, Fukada Y. Resetting mechanism of central and peripheral circadian clocks in mammals. Zoolog Sci. 2004; 21: 359-68.
16. Zhu H, Vadigepalli R, Rafferty R, Gonye GE, Weaver DR, Schwaber JS. Integrative gene regulatory network analysis reveals light-induced regional gene expression phase shift programs in the mouse suprachiasmatic nucleus. PLoS One. 2012; 7: e37833.
17. Gerber A, Esnault C, Aubert G, Treisman R, Pralong F, Schibler U. Blood-borne circadian signal stimulates daily oscillations in actin dynamics and SRF activity. Cell. 2013; 152: 492-503.
18. Barclay JL, Tsang AH, Oster H. Interaction of central and peripheral clocks in physiological regulation. Prog Brain Res. 2012; 199: 163-81.
19. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010; 5: e10995.
20. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003; 3: 350-61.
21. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003; 302: 255-9.
22. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41-50.
23. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell. 2005; 122: 803-15.
24. Gu X, Xing L, Shi G, Liu Z, Wang X, Qu Z, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ. 2012; 19: 397-405.
25. Geyfman M, Kumar V, Liu Q, Ruiz R, Gordon W, Espitia F, et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci U S A. 2012; 109: 11758-63.
26. Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, Xiong Y, et al. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem. 2009; 145: 289-97.
27. Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008; 6: 1786-93.
28. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22: 375-82.
29. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005; 25: 3109-16.
30. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13: 11-26.
31. Massague J. G1 cell-cycle control and cancer. Nature. 2004; 432: 298-306.
32. Brodal P. The central nervous system: structure and function. New York: Oxford University Press; 2010.
33. Adams SL, Roxe DM, Weiss J, Zhang F, Rosenthal JE. Ambulatory blood pressure and Holter monitoring of emergency physicians before, during, and after a night shift. Acad Emerg Med. 1998; 5: 871-7.
34. Raju B, Haug SR, Ibrahim SO, Heyeraas KJ. Sympathectomy decreases size and invasiveness of tongue cancer in rats. Neuroscience. 2007; 149: 715-25.
35. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341: 1236361.
36. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94: 690-7.
37. Li JC, Xu F. Influences of light-dark shift ing on the immune system, tumor growth and life span of rats, mice and fruit flies as well as on the counteraction of melatonin. Biol Signals. 1997; 6: 77-89.
38. Wu M, Zeng J, Chen Y, Zeng Z, Zhang J, Cai Y, et al. Experimental chronic jet lag promotes growth and lung metastasis of Lewis lung carcinoma in C57BL/6 mice. Oncol Rep. 2012; 27: 1417-28.
39. Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res. 2009; 680: 95-105.
40. Logan RW, Zhang C, Murugan S, O'Connell S, Levitt D, Rosenwasser AM, et al. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats. J Immunol. 2012; 188: 2583-91.
41. Yasuniwa Y, Izumi H, Wang KY, Shimajiri S, Sasaguri Y, Kawai K, et al. Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway. PLoS One. 2010; 5: e15330.
42. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotatingshift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006; 164: 549-55.
43. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res. 2007; 67: 10618-22.
44. Lahti TA, Partonen T, Kyyronen P, Kauppinen T, Pukkala E. Night-time work predisposes to non-Hodgkin lymphoma. Int J Cancer. 2008; 123: 2148-51.
45. Stevens RG. Working against our endogenous circadian clock: breast cancer and electric lighting in the modern world. Mutat Res. 2009; 680: 106-8.
46. Touitou Y, Bogdan A, Levi F, Benavides M, Auzeby A. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Br J Cancer. 1996; 74: 1248-52.
47. Panzer A. Melatonin in osteosarcoma: an effective drug? Med Hypotheses. 1997; 48: 523-5.
48. Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2004; 13: 779-86.
49. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009; 281: 1-7.
50. Kloog I, Haim A, Stevens RG, Portnov BA. Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. Chronobiol Int. 2009; 26: 108-25.
51. Knutsson A, Alfredsson L, Karlsson B, Akerstedt T, Fransson EI, Westerholm P, et al. Breast cancer among shift workers: results of the WOLF longitudinal cohort study. Scand J Work Environ Health. 2013; 39: 170-7.
52. Bhatti P, Mirick DK, Davis S. Invited commentary: shift work and cancer. Am J Epidemiol. 2012; 176: 760- 3; discussion 764-5.
53. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013; 17: 273-84.
54. Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol. 1993; 88: 1744-8.
55. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001; 93: 1557-62.
56. Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001; 12: 95-101.
57. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001; 93: 1563-8.
58. Pukkala E, Aspholm R, Auvinen A, Eliasch H, Gundestrup M, Haldorsen T, et al. Cancer incidence among 10,211 airline pilots: a Nordic study. Aviat Space Environ Med. 2003; 74: 699-706.
59. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004; 432: 316-23.
60. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411: 342-8.
61. Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A. 2010; 107: 4890-5.
62. Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci U S A. 2011; 108: 18790-5.
63. Cotta-Ramusino C, McDonald ER 3rd, Hurov K, Sowa ME, Harper JW, Elledge SJ. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science. 2011; 332: 1313-17.
64. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. Alarge scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 2009; 4: e4798.
65. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev. 2006; 20: 1868-73.
66. Antoch MP, Gorbacheva VY, Vykhovanets O, Toshkov IA, Kondratov RV, Kondratova AA, et al. Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle. 2008; 7: 1197-204.
67. Gauger MA, Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 2005; 65: 6828-34.
68. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013; 75: 685-705.
69. Best BP. Nuclear DNA damage as a direct cause of aging. Rejuvenation Res. 2009; 12: 199-208.
70. Sager R. Senescence as a mode of tumor suppression. Environ Health Perspect. 1991; 93: 59-62.
71. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene. 2013; 32: 5129-43.
72. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006; 126: 257-68.
73. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107: 149-59.
74. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, et al. The NAD +-dependent deacetylase SIRT1 modulates CLOCKmediated chromatin remodeling and circadian control. Cell. 2008; 134: 329-40.
75. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, Kreppel F, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008; 134: 317-28.
76. Chang HC, Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell. 2013; 153: 1448-60.
77. Cho IR, Koh SS, Malilas W, Srisuttee R, Moon J, Choi YW, et al. SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of beta-catenin. Biochem Biophys Res Commun. 2012; 423: 270-5.
78. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med. 2007; 39: 8-13.
79. Khapre RV, Kondratova AA, Susova O, Kondratov RV. Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle. 2011; 10: 4162-9.
80. Wang CY, Wen MS, Wang HW, Hsieh IC, Li Y, Liu PY, et al. Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation. 2008; 118: 2166-73.
81. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003; 17: 1195-214.
82. De Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis. 2004; 19: 169-85.
83. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39: 44-84.
84. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012; 16: 1295-322.
85. Dang CV. Links between metabolism and cancer. Genes Dev. 2012; 26: 877-90.
86. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002; 109: 307-20.
87. Cipolla-Neto J, Abdalla DS, Markus RP, Campa A. Circadian variations of superoxide dismutase activity in the rat pineal gland. J Neural Transm Gen Sect. 1993; 92: 117-23.
88. Anea CB, Zhang M, Chen F, Ali MI, Hart CM, Stepp DW, et al. Circadian clock control of Nox4 and reactive oxygen species in the vasculature. PLoS One. 2013; 8: e78626.
89. Warburg O. On the origin of cancer cells. Science. 1956; 123: 309-14.
90. Duffield GE, Best JD, Meurers BH, Bittner A, Loros JJ, Dunlap JC. Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells. Curr Biol. 2002; 12: 551-7.
91. Bass J, Turek FW. Sleepless in America: a pathway to obesity and the metabolic syndrome? Arch Intern Med. 2005; 165: 15-16.
92. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4: 221-33.
93. Okwan-Duodu D, Umpierrez GE, Brawley OW, Diaz R. Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res. 2013; 3: 21-33.
94. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci. 2012; 1271: 82-7.
95. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431-6.
96. Woon PY, Kaisaki PJ, Braganca J, Bihoreau MT, Levy JC, Farrall M, et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A. 2007; 104: 14412-7.
97. Popa-Wagner A, Catalin B, Buga AM. Novel putative mechanisms to link circadian clocks to healthy aging. J Neural Transm. 2013 Dec 3. [Epub ahead of print].
98. Milagro FI, Gomez-Abellan P, Campion J, Martinez JA, Ordovas JM, Garaulet M. CLOCK, PER2 and BMAL1 DNA methylation: association with obesity and metabolic syndrome characteristics and monounsaturated fat intake. Chronobiol Int. 2012; 29: 1180-94.
99. Partonen T, Treutlein J, Alpman A, Frank J, Johansson C, Depner M, et al. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med. 2007; 39: 229-38.
100. Evans DS, Parimi N, Nievergelt CM, Blackwell T, Redline S, Ancoli-Israel S, et al. Common genetic variants in ARNTL and NPAS2 and at chromosome 12p13 are associated with objectively measured sleep traits in the elderly. Sleep. 2013; 36: 431-46.
101. Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal. 2013; 25: 1828-36.
102. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009; 69: 9315-22.
103. Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ, Arafat HA. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J Gastrointest Surg. 2013; 17: 443-50.
104. Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J, Higashimoto M, Mashiko M, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008; 87: 1060-70.
105. Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol. 2012; 33: 149-55.
106. Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 2009; 69: 8447-54.
107. Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HY, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006; 97: 1298-307.
108. Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, et al. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int J Cancer. 2012; 131: 2820-31.
109. Zeng ZL, Wu MW, Sun J, Sun YL, Cai YC, Huang YJ, et al. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem. 2010; 148: 319-26.
110. Jung CH, Kim EM, Park JK, Hwang SG, Moon SK, Kim WJ, et al. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep. 2013; 29: 2109-13.
111. Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, et al. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell. 2000; 103: 1009-17.
112. Bunger MK, Walisser JA, Sullivan R, Manley PA, Moran SM, Kalscheur VL, et al. Progressive arthropathy in mice with a targeted disruption of the Mop3/Bmal-1 locus. Genesis. 2005; 41: 122-32.
113. Kondratova AA, Kondratov RV. The circadian clock and pathology of the ageing brain. Nat Rev Neurosci. 2012; 13: 325-35.
114. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/ BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005; 102: 3407-12.
115. Paschos GK, Ibrahim S, Song WL, Kunieda T, Grant G, Reyes TM, et al. Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med. 2012; 18: 1768-77.
116. Marcheva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010; 466: 627-31.
117. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYCdriven cancer. Proc Natl Acad Sci U S A. 2012; 109: 9545-50.
118. Li S, Chen XW, Yu L, Saltiel AR, Lin JD. Circadian metabolic regulation through crosstalk between casein kinase 1delta and transcriptional coactivator PGC-1alpha. Mol Endocrinol. 2011; 25: 2084-93.
119. Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature. 2007; 447: 477-81.
120. Tsai IC, Woolf M, Neklason DW, Branford WW, Yost HJ, Burt RW, et al. Disease-associated casein kinase Idelta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. Int J Cancer. 2007; 120: 1005-12.
121. Rodriguez N, Yang J, Hasselblatt K, Liu S, Zhou Y, Rauh-Hain JA, et al. Casein kinase Iepsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells. EMBO Mol Med. 2012; 4: 952-63.
122. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7: e31127.
123. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, et al. CK1epsilon is required for breast cancers dependent on betacatenin activity. PLoS One. 2010; 5: e8979.
124. Brockschmidt C, Hirner H, Huber N, Eismann T, Hillenbrand A, Giamas G, et al. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut. 2008; 57: 799-806.
125. Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 2008; 11: 342-8.
126. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011; 28: 841-51.
127. Li L, Zhao D, Wei H, Yao L, Dang Y, Amjad A, et al. REGgamma defi-ciency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013; 110: 11005-10.
128. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging. 2000; 21: 503-10.
129. Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y, et al. Casein kinase idelta mutations in familial migraine and advanced sleep phase. Sci Transl Med. 2013; 5: 183ra56, 1-11.
130. Perez DI, Gil C, Martinez A. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev. 2011; 31: 924-54.
131. Xu Y, Padiath QS, Shapiro RE, Jones CR, Wu SC, Saigoh N, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005; 434: 640-4.
132. Miao CG, Yang YY, He X, Li XF, Huang C, Huang Y, et al. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal. 2013; 25: 2069-78.
133. Garcia-Ibarbia C, Delgado-Calle J, Casafont I, Velasco J, Arozamena J, Perez-Nunez MI, et al. Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders. Gene. 2013; 532: 165-72.
134. Hernandez-Morante JJ, Gomez-Santos C, Margareto J, Formiguera X, Martinez CM, Gonzalez R, et al. Influence of menopause on adipose tissue clock gene genotype and its relationship with metabolic syndrome in morbidly obese women. Age. 2012; 34: 1369-80.
135. Soliman NA, Zineldeen DH, El-Khadrawy OH. Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer. Asian Pac J Cancer Prev. 2014; 15: 837-45.
136. Etchegaray JP, Machida KK, Noton E, Constance CM, Dallmann R, Di Napoli MN, et al. Casein kinase 1 delta regulates the pace of the mammalian circadian clock. Mol Cell Biol. 2009; 29: 3853-66.
137. Hirner H, Gunes C, Bischof J, Wolff S, Grothey A, Kuhl M, et al. Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo. PLoS One. 2012; 7: e29709.
138. Ghosh S, Koralov SB, Stevanovic I, Sundrud MS, Sasaki Y, Rajewsky K, et al. Hyperactivation of nuclear factor of activated Tcells 1 (NFAT1) in Tcells attenuates severity of murine autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010; 107: 15169-74.
139. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat. 2011; 127: 531-40.
140. Lengyel Z, Lovig C, Kommedal S, Keszthelyi R, Szekeres G, Battyani Z, et al. Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors. Tumour Biol. 2013; 34: 811-19.
141. Rana S, Munawar M, Shahid A, Malik M, Ullah H, Fatima W, et al. Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia. Mol Biol Rep. 2014; 41: 95-103.
142. Gomez-Abellan P, Gomez-Santos C, Madrid JA, Milagro FI, Campion J, Martinez JA, et al. Circadian expression of adiponectin and its receptors in human adipose tissue. Endocrinology. 2010; 151: 115-22.
143. Garaulet M, Lee YC, Shen J, Parnell LD, Arnett DK, Tsai MY, et al. CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr. 2009; 90: 1466-75.
144. Sookoian S, Castano G, Gemma C, Gianotti TF, Pirola CJ. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2007; 13: 4242-8.
145. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science. 1994; 264: 719-25.
146. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005; 308: 1043-5.
147. Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol. 2004; 2: e377.
148. Spengler ML, Kuropatwinski KK, Comas M, Gasparian AV, Fedtsova N, Gleiberman AS, et al. Core circadian protein CLOCK is a positive regulator of NF-kappaB-mediated transcription. Proc Natl Acad Sci U S A. 2012; 109: E2457-65.
149. Bray MS, Shaw CA, Moore MW, Garcia RA, Zanquetta MM, Durgan DJ, et al. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am J Physiol Heart Circ Physiol. 2008; 294: H1036-47.
150. Dubrovsky YV, Samsa WE, Kondratov RV. Deficiency of circadian protein CLOCK reduces lifespan and increases age-related cataract development in mice. Aging. 2010; 2: 936-44.
151. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009; 324: 651-4.
152. Oishi K, Miyazaki K, Kadota K, Kikuno R, Nagase T, Atsumi G, et al. Genome-wide expression analysis of mouse liver reveals CLOCKregulated circadian output genes. J Biol Chem. 2003; 278: 41519-27.
153. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1928-36.
154. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, et al. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res. 2009; 69: 3605-13.
155. Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, et al. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010; 70: 1459-68.
156. Luo Y, Wang F, Chen LA, Chen XW, Chen ZJ, Liu PF, et al. Deregulated expression of cry1 and cry2 in human gliomas. Asian Pac J Cancer Prev. 2012; 13: 5725-8.
157. Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, et al. Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms. 2011; 26: 136-48.
158. Eisele L, Prinz R, Klein-Hitpass L, Nuckel H, Lowinski K, Thomale J, et al. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol. 2009; 83: 320-7.
159. Mannic T, Meyer P, Triponez F, Pusztaszeri M, Le Martelot G, Mariani O, et al. Circadian clock characteristics are altered in human thyroid malignant nodules. J Clin Endocrinol Metab. 2013; 98: 4446-56.
160. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008; 47: 925-33.
161. Roe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H, et al. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One. 2009; 4: e6554.
162. Lin Q, Ding H, Zheng Z, Gu Z, Ma J, Chen L, et al. Promoter methylation analysis of seven clock genes in Parkinson's disease. Neurosci Lett. 2012; 507: 147-50.
163. Soria V, Martinez-Amoros E, Escaramis G, Valero J, Perez-Egea R, Garcia C, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology. 2010; 35: 1279-89.
164. Haimovich B, Calvano J, Haimovich AD, Calvano SE, Coyle SM, Lowry SF. In vivo endotoxin synchronizes and suppresses clock gene expression in human peripheral blood leukocytes. Crit Care Med. 2010; 38: 751-8.
165. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42: 105-16.
166. Hu C, Zhang R, Wang C, Wang J, Ma X, Hou X, et al. Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One. 2010; 5: e15542.
167. Barker A, Sharp SJ, Timpson NJ, Bouatia-Naji N, Warrington NM, Kanoni S, et al. Association of genetic Loci with glucose levels in childhood and adolescence: a meta-analysis of over 6,000 children. Diabetes. 2011; 60: 1805-12.
168. Gomez-Abellan P, Hernandez-Morante JJ, Lujan JA, Madrid JA, Garaulet M. Clock genes are implicated in the human metabolic syndrome. Int J Obes (Lond). 2008; 32: 121-8.
169. Pappa KI, Gazouli M, Anastasiou E, Iliodromiti Z, Antsaklis A, Anagnou NP. Circadian clock gene expression is impaired in gestational diabetes mellitus. Gynecological Endocrinology: The Official Journal Of The International Society Of Gynecological Endocrinology. 2013; 29: 331-5.
170. Tahira K, Ueno T, Fukuda N, Aoyama T, Tsunemi A, Matsumoto S, et al. Obesity alters the expression profile of clock genes in peripheral blood mononuclear cells. Arch Med Sci. 2011; 7: 933-40.
171. Kelly MA, Rees SD, Hydrie MZ, Shera AS, Bellary S, O'Hare JP, et al. Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One. 2012; 7: e32670.
172. Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, et al. Phenotypic effects of the circadian gene Cryptochrome 2 on cancerrelated pathways. BMC Cancer. 2010; 10: 110.
173. Maronde E, Schilling AF, Seitz S, Schinke T, Schmutz I, van der Horst G, et al. The clock genes Period 2 and Cryptochrome 2 differentially balance bone formation. PLoS One. 2010; 5: e11527.
174. Tong X, Buelow K, Guha A, Rausch R, Yin L. USP2a protein deubiquitinates and stabilizes the circadian protein CRY1 in response to inflammatory signals. J Biol Chem. 2012; 287: 25280-91.
175. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl Acad Sci U S A. 2012; 109: 12662-7.
176. Barclay JL, Shostak A, Leliavski A, Tsang AH, Johren O, Muller-Fielitz H, et al. High-fat diet-induced hyperinsulinemia and tissue-specific insulin resistance in Cry-deficient mice. Am J Physiol Endocrinol Metab. 2013; 304: E1053-63.
177. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 2010; 16: 67-74.
178. Wisor JP, O'Hara BF, Terao A, Selby CP, Kilduff TS, Sancar A, et al. Arole for cryptochromes in sleep regulation. BMC Neurosci. 2002; 3: 20.
179. Kawamoto T, Noshiro M, Sato F, Maemura K, Takeda N, Nagai R, et al. Anovel autofeedback loop of Dec1 transcription involved in circadian rhythm regulation. Biochem Biophys Res Commun. 2004; 313: 117-24.
180. Hamaguchi H, Fujimoto K, Kawamoto T, Noshiro M, Maemura K, Takeda N, et al. Expression of the gene for Dec2, a basic helix-loophelix transcription factor, is regulated by a molecular clock system. Biochem J. 2004; 382(Pt 1): 43-50.
181. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature. 2002; 419: 841-4.
182. Nishiwaki T, Daigo Y, Kawasoe T, Nakamura Y. Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000; 27: 169-76.
183. Miura K, Suzuki K, Tokino T, Isomura M, Inazawa J, Matsuno S, et al. Detailed deletion mapping in squamous cell carcinomas of the esophagus narrows a region containing a putative tumor suppressor gene to about 200 kilobases on distal chromosome 9q. Cancer Res. 1996; 56: 1629-34.
184. Wong VC, Ko JM, Qi RZ, Li PJ, Wang LD, Li JL, et al. Abrogated expression of DEC1 during oesophageal squamous cell carcinoma progression is age-and family history-related and significantly associated with lymph node metastasis. Br J Cancer. 2011; 104: 841-9.
185. Jia YF, Xiao DJ, Ma XL, Song YY, Hu R, Kong Y, et al. Differentiated embryonic chondrocyte-expressed gene 1 is associated with hypoxiainducible factor 1alpha and Ki67 in human gastric cancer. Diagn Pathol. 2013; 8: 37.
186. Liu Y, Miao Y, Wang J, Lin X, Wang L, Xu HT, et al. DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1. Int J Mol Med. 2013; 31: 855-60.
187. Liu Y, Wang L, Lin XY, Wang J, Yu JH, Miao Y, et al. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells. Tumour Biol. 2013; 34: 1641-50.
188. Wu Y, Sato F, Yamada T, Bhawal UK, Kawamoto T, Fujimoto K, et al. The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cancer. Int J Oncol. 2012; 41: 1337-46.
189. Wei H, Ke HL, Lin J, Shete S, Wood CG, Hildebrandt MA. MicroRNA target site polymorphisms in the VHL-HIF1alpha pathway predict renal cell carcinoma risk. Mol Carcinog. 2014; 53: 1-7.
190. Shi XH, Zheng Y, Sun Q, Cui J, Liu QH, Qu F, et al. DEC1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. World J Gastroenterology. 2011; 17: 2037-43.
191. Yunokawa M, Tanimoto K, Nakamura H, Nagai N, Kudo Y, Kawamoto T, et al. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas. Oncol Rep. 2007; 17: 871-8.
192. Moller-Levet CS, Archer SN, Bucca G, Laing EE, Slak A, Kabiljo R, et al. Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. Proc Natl Acad Sci U S A. 2013; 110: E1132-41.
193. Martinez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, et al. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ Tcell response. J Exp Med. 2013; 210: 1603-19.
194. Bhawal UK, Ito Y, Tanimoto K, Sato F, Fujimoto K, Kawamoto T, et al. IL-1beta-mediated up-regulation of DEC1 in human gingiva cells via the Akt pathway. J Cell Biochem. 2012; 113: 3246-53.
195. Rossner MJ, Oster H, Wichert SP, Reinecke L, Wehr MC, Reinecke J, et al. Disturbed clockwork resetting in Sharp-1 and Sharp-2 single and double mutant mice. PLoS One. 2008; 3: e2762.
196. Nakashima A, Kawamoto T, Honda KK, Ueshima T, Noshiro M, Iwata T, et al. DEC1 modulates the circadian phase of clock gene expression. Mol Cell Biol. 2008; 28: 4080-92.
197. Englund A, Kovanen L, Saarikoski ST, Haukka J, Reunanen A, Aromaa A, et al. NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms. 2009; 7: 5.
198. Smith AK, Fang H, Whistler T, Unger ER, Rajeevan MS. Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. Neuropsychobiology. 2011; 64: 183-94.
199. Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat. 2008; 107: 421-5.
200. Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. Int J Cancer. 2012; 131: 2547-52.
201. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer. 2007; 120: 432-5.
202. Yi C, Mu L, de la Longrais IA, Sochirca O, Arisio R, Yu H, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat. 2010; 120: 663-9.
203. Liu Y, Zhang X, Liu J, Hou G, Zhang S, Zhang J. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. Tumour Biol. 2014; 35: 1275-86.
204. Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, et al. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control. 2014; 25: 25-32.
205. Wu X, Wiater MF, Ritter S. NPAS2 deletion impairs responses to restricted feeding but not to metabolic challenges. Physiol Behav. 2010; 99: 466-71.
206. O'Neil D, Mendez-Figueroa H, Mistretta TA, Su C, Lane RH, Aagaard KM. Dysregulation of Npas2 leads to altered metabolic pathways in a murine knockout model. Mol Genet Metab. 2013; 110: 378-87.
207. Franken P, Dudley CA, Estill SJ, Barakat M, Thomason R, O'Hara BF, et al. NPAS2 as a transcriptional regulator of non-rapid eye movement sleep: genotype and sex interactions. Proc Natl Acad Sci U S A. 2006; 103: 7118-23.
208. Dudley CA, Erbel-Sieler C, Estill SJ, Reick M, Franken P, Pitts S, et al. Altered patterns of sleep and behavioral adaptability in NPAS2-defi-cient mice. Science. 2003; 301: 379-83.
209. Anantharam V, Lehrmann E, Kanthasamy A, Yang Y, Banerjee P, Becker KG, et al. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem Int. 2007; 50: 834-47.
210. Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001; 293: 510-14.
211. Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y. Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett. 2009; 284: 149-56.
212. Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 2008; 6: 1461-8.
213. Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009; 48: 642-7.
214. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 2007; 9: 797-800.
215. Xia HC, Niu ZF, Ma H, Cao SZ, Hao SC, Liu ZT, et al. Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci. 2010; 37: 365-70.
216. Fujioka A, Takashima N, Shigeyoshi Y. Circadian rhythm generation in a glioma cell line. Biochem Biophys Res Commun. 2006; 346: 169-74.
217. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26: 1241-6.
218. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010; 49: 60-8.
219. Oda A, Katayose Y, Yabuuchi S, Yamamoto K, Mizuma M, Shirasou S, et al. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res. 2009; 29: 1201-9.
220. Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC. Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett. 2006; 243: 55-7.
221. Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 1399-404.
222. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, et al. Arole for the clock gene per1 in prostate cancer. Cancer Res. 2009; 69: 7619-25.
223. Thoennissen NH, Thoennissen GB, Abbassi S, Nabavi-Nouis S, Sauer T, Doan NB, et al. Transcription factor CCAAT/enhancerbinding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53: 1577-85.
224. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res. 2011; 51: 259-69.
225. Sun CM, Huang SF, Zeng JM, Liu DB, Xiao Q, Tian WJ, et al. Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction. Pathol Oncol Res. 2010; 16: 403-11.
226. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009; 13: 257-64.
227. Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM. Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms. 2008; 6: 4.
228. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007; 26: 7916-20.
229. Chu LW, Zhu Y, Yu K, Zheng T, Chokkalingam AP, Stanczyk FZ, et al. Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3268-73.
230. Garaulet M, Corbalan-Tutau MD, Madrid JA, Baraza JC, Parnell LD, Lee YC, et al. PERIOD2 variants are associated with abdominal obesity, psycho-behavioral factors, and attrition in the dietary treatment of obesity. J Am Diet Assoc. 2010; 110: 917-21.
231. Garcia-Rios A, Perez-Martinez P, Delgado-Lista J, Phillips CM, Gjelstad IM, Wright JW, et al. A Period 2 genetic variant interacts with plasma SFA to modify plasma lipid concentrations in adults with metabolic syndrome. J Nutr. 2012; 142: 1213-18.
232. Lazar AS, Santhi N, Hasan S, Lo JC, Johnston JD, Von Schantz M, et al. Circadian period and the timing of melatonin onset in men and women: predictors of sleep during the weekend and in the laboratory. J Sleep Res. 2013; 22: 155-9.
233. Below JE, Gamazon ER, Morrison JV, Konkashbaev A, Pluzhnikov A, McKeigue PM, et al. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia. 2011; 54: 2047-55.
234. Guess J, Burch JB, Ogoussan K, Armstead CA, Zhang H, Wagner S, et al. Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther. 2009; 8: 329-36.
235. Hida A, Kusanagi H, Satoh K, Kato T, Matsumoto Y, Echizenya M, et al. Expression profiles of PERIOD1, 2, and 3 in peripheral blood mononuclear cells from older subjects. Life Sci. 2009; 84: 33-7.
236. Jud C, Chappuis S, Revell VL, Sletten TL, Saaltink DJ, Cajochen C, et al. Age-dependent alterations in human PER2 levels after early morning blue light exposure. Chronobiol Int. 2009; 26: 1462-9.
237. Lin C, Tang X, Zhu Z, Liao X, Zhao R, Fu W, et al. The rhythmic expression of clock genes attenuated in human plaque-derived vascular smooth muscle cells. Lipids Health Dis. 2014; 13: 14.
238. Shiino Y, Nakajima S, Ozeki Y, Isono T, Yamada N. Mutation screening of the human period 2 gene in bipolar disorder. Neurosci Lett. 2003; 338: 82-4.
239. Yoshida K, Hashiramoto A, Okano T, Yamane T, Shibanuma N, Shiozawa S. TNF-alpha modulates expression of the circadian clock gene Per2 in rheumatoid synovial cells. Scand J Rheumatol. 2013; 42: 276-80.
240. Ojeda DA, Perea CS, Nino CL, Gutierrez RM, Lopez-Leon S, Arboleda H, et al. Anovel association of two non-synonymous polymorphisms in PER2 and PER3 genes with specific diurnal preference subscales. Neurosci Lett. 2013; 553: 52-6.
241. Nakamura Y, Harama D, Shimokawa N, Hara M, Suzuki R, Tahara Y, et al. Circadian clock gene Period2 regulates a time-of-day-dependent variation in cutaneous anaphylactic reaction. J Allergy Clin Immunol. 2011; 127: 1038-45 e1-3.
242. Pilorz V, Steinlechner S. Low reproductive success in Per1 and Per2 mutant mouse females due to accelerated ageing? Reproduction. 2008; 135: 559-68.
243. Spencer S, Falcon E, Kumar J, Krishnan V, Mukherjee S, Birnbaum SG, et al. Circadian genes Period 1 and Period 2 in the nucleus accumbens regulate anxiety-related behavior. Eur J Neurosci. 2013; 37: 242-50.
244. Liu J, Malkani G, Shi X, Meyer M, Cunningham-Runddles S, Ma X, et al. The circadian clock Period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect Immun. 2006; 74: 4750-6.
245. Bonney S, Kominsky D, Brodsky K, Eltzschig H, Walker L, Eckle T. Cardiac Per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart. PLoS One. 2013; 8: e71493.
246. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med. 2012; 18: 774-82.
247. Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J, Amin RH, et al. PER2 controls lipid metabolism by direct regulation of PPARgamma. Cell Metab. 2010; 12: 509-20.
248. Bhatwadekar AD, Yan Y, Qi X, Thinschmidt JS, Neu MB, Li Calzi S, et al. Per2 mutation recapitulates the vascular phenotype of diabetes in the retina and bone marrow. Diabetes. 2013; 62: 273-82.
249. Cheng B, Anea CB, Yao L, Chen F, Patel V, Merloiu A, et al. Tissue-intrinsic dysfunction of circadian clock confers transplant arteriosclerosis. Proc Natl Acad Sci U S A. 2011; 108: 17147-52.
250. Carvas JM, Vukolic A, Yepuri G, Xiong Y, Popp K, Schmutz I, et al. Period2 gene mutant mice show compromised insulin-mediated endothelial nitric oxide release and altered glucose homeostasis. Front Physiol. 2012; 3: 337.
251. Ma K, Xiao R, Tseng HT, Shan L, Fu L, Moore DD. Circadian dysregulation disrupts bile acid homeostasis. PLoS One. 2009; 4: e6843.
252. Logan RW, Wynne O, Levitt D, Price D, Sarkar DK. Altered circadian expression of cytokines and cytolytic factors in splenic natural killer cells of Per1(-/-) mutant mice. J Interferon Cytokine Res. 2013; 33: 108-14.
253. Arjona A, Sarkar DK. The circadian gene mPer2 regulates the daily rhythm of IFN-gamma. J Interferon Cytokine Res. 2006; 26: 645-9.
254. Arjona A, Sarkar DK. Evidence supporting a circadian control of natural killer cell function. Brain Behav Immun. 2006; 20: 469-76.
255. Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, et al. Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat. 2013; 142: 211-23.
256. Mond M, Alexiadis M, Eriksson N, Davis M, Muscat G, Fuller P, et al. Nuclear receptor expression in human differentiated thyroid tumors. Thyroid. 2014 Feb 21. [Epub ahead of print]
257. Xiong G, Wang C, Evers BM, Zhou BP, Xu R. RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res. 2012; 72: 1728-39.
258. Moretti RM, Montagnani Marelli M, Sala A, Motta M, Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer. 2004; 112: 87-93.
259. Karasek M, Gruszka A, Lawnicka H, Kunert-Radek J, Pawlikowski M. Melatonin inhibits growth of diethylstilbestrol-induced prolactinsecreting pituitary tumor in vitro: possible involvement of nuclear RZR/ROR receptors. J Pineal Res. 2003; 34: 294-6.
260. Kottorou AE, Antonacopoulou AG, Dimitrakopoulos FI, Tsamandas AC, Scopa CD, Petsas T, et al. Altered expression of NFY-C and RORA in colorectal adenocarcinomas. Acta Histochem. 2012; 114: 553-61.
261. Ramasamy A, Kuokkanen M, Vedantam S, Gajdos ZK, Couto Alves A, Lyon HN, et al. Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA. PLoS One. 2012; 7: e44008.
262. Klar J, Asling B, Carlsson B, Ulvsback M, Dellsen A, Strom C, et al. RARrelated orphan receptor Aisoform 1 (RORa1) is disrupted by a balanced translocation t(4;15)(q22.3;q21.3) associated with severe obesity. European Journal Of Human Genetics: EJHG. 2005; 13: 928-34.
263. Gamboa-Melendez MA, Huerta-Chagoya A, Moreno-Macias H, Vazquez-Cardenas P, Ordonez-Sanchez ML, Rodriguez-Guillen R, et al. Contribution of common genetic variation to the risk of type 2 diabetes in the Mexican Mestizo population. Diabetes. 2012; 61: 3314-21.
264. Tinahones FJ, Moreno-Santos I, Vendrell J, Chacon MR, Garrido-Sanchez L, Garcia-Fuentes E, et al. The retinoic acid receptor-related orphan nuclear receptor gamma1 (RORgamma1): a novel player determinant of insulin sensitivity in morbid obesity. Obesity. 2012; 20: 488-97.
265. Kurebayashi S, Ueda E, Sakaue M, Patel DD, Medvedev A, Zhang F, et al. Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci U S A. 2000; 97: 10132-7.
266. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science. 2000; 288: 2369-73.
267. Jetten AM, Kang HS, Takeda Y. Retinoic acid-related orphan receptors alpha and gamma: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front Endocrinol (Lausanne). 2013; 4: 1.
268. Meissburger B, Ukropec J, Roeder E, Beaton N, Geiger M, Teupser D, et al. Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol Med. 2011; 3: 637-51.
269. Crumbley C, Wang Y, Banerjee S, Burris TP. Regulation of expression of citrate synthase by the retinoic acid receptor-related orphan receptor alpha (RORalpha). PLoS One. 2012; 7: e33804.
270. Gohil K, Godzdanker R, O'Roark E, Schock BC, Kaini RR, Packer L, et al. Alpha-tocopherol transfer protein deficiency in mice causes multi-organ deregulation of gene networks and behavioral deficits with age. Ann N Y Acad Sci. 2004; 1031: 109-26.
271. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernandez C, Soria-Valles C, De Gonzalo-Calvo D, et al. Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescence-accelerated mice. J Pineal Res. 2008; 45: 302-11.
272. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REVERB-beta. Nature. 2012; 485: 123-7.
273. Muscat GE, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, et al. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol. 2013; 27: 350-65.
274. Davis LM, Harris C, Tang L, Doherty P, Hraber P, Sakai Y, et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn. 2007; 9: 327-36.
275. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10: 529-41.
276. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res. 2010; 70: 1783-92.
277. Goumidi L, Grechez A, Dumont J, Cottel D, Kafatos A, Moreno LA, et al. Impact of REV-ERB alpha gene polymorphisms on obesity phenotypes in adult and adolescent samples. Int J Obes (Lond). 2013; 37: 666-72.
278. Garaulet M, Smith CE, Gomez-Abellan P, Ordovas-Montanes M, Lee YC, Parnell LD, et al. REV-ERB-ALPHA circadian gene variant associates with obesity in two independent populations: Mediterranean and North American. Mol Nutr Food Res. 2014; 58: 821-9.
279. Thessen Hedreul M, Moller S, Stridh P, Gupta Y, Gillett A, Daniel Beyeen A, et al. Combining genetic mapping with genome-wide expression in experimental autoimmune encephalomyelitis highlights a gene network enriched for Tcell functions and candidate genes regulating autoimmunity. Hum Mol Genet. 2013; 22: 4952-66.
280. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut. 2013; 62: 985-94.
281. Delezie J, Dumont S, Dardente H, Oudart H, Grechez-Cassiau A, Klosen P, et al. The nuclear receptor REV-ERBalpha is required for the daily balance of carbohydrate and lipid metabolism. FASEB J. 2012; 26: 3321-35.
282. Gibbs JE, Blaikley J, Beesley S, Matthews L, Simpson KD, Boyce SH, et al. The nuclear receptor REV-ERBalpha mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci U S A. 2012; 109: 582-7.
283. Ohsaki K, Oishi K, Kozono Y, Nakayama K, Nakayama KI, Ishida N. The role of {beta}-TrCP1 and {beta}-TrCP2 in circadian rhythm generation by mediating degradation of clock protein PER2. J Biochem. 2008; 144: 609-18.
284. Kim CJ, Song JH, Cho YG, Kim YS, Kim SY, Nam SW, et al. Somatic mutations of the beta-TrCP gene in gastric cancer. APMIS. 2007; 115: 127-33.
285. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IeM, Buhler K, et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer. 2002; 34: 9-16.
286. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-13.
287. Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, et al. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, betacatenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst. 2004; 96: 1161-70.
288. Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G, et al. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 2005; 65: 1316-24.
289. Chen S, He Y, Ding J, Jiang Y, Jia S, Xia W, et al. An insertion/deletion polymorphism in the 3'untranslated region of beta-transducin repeatcontaining protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun. 2010; 391: 552-6.
290. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, et al. Degradation of Cdc25A by beta-TrCP during Sphase and in response to DNA damage. Nature. 2003; 426: 87-91.
291. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, et al. Control of meiotic and mitotic progression by the Fbox protein beta-Trcp1 in vivo. Dev Cell. 2003; 4: 799-812.
292. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1-and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006; 314: 467-71.
293. Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. mTOR generates an auto-amplification loop by triggering the betaTrCP-and CK1alpha-dependent degradation of DEPTOR. Mol Cell. 2011; 44: 317-24.
294. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011; 44: 304-16.
295. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and betacatenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999; 13: 270-83.
296. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, et al. betaTrCP-and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell. 2009; 33: 109-16.
297. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, et al. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012; 209: 1289-307.
298. Kudo Y, Guardavaccaro D, Santamaria PG, Koyama-Nasu R, Latres E, Bronson R, et al. Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol. 2004; 24: 8184-94.
299. Belaidouni N, Peuchmaur M, Perret C, Florentin A, Benarous R, Besnard-Guerin C. Overexpression of human beta TrCP1 deleted of its Fbox induces tumorigenesis in transgenic mice. Oncogene. 2005; 24: 2271-6.
300. Huang C. Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr. 2010; 4: 10-18.
301. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A. 2004; 101: 4419-24.
302. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, et al. Phosphorylation by casein kinase Ipromotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell. 2010; 18: 147-59.
303. Roenneberg T. Chronobiology: the human sleep project. Nature. 2013; 498: 427-8.